Benefits were observed in patients across a spectrum of renal risk, but were evident also in those without renal damage, suggesting a role for SGLT2 inhibition in the prevention of CKD in people with T2D. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.